Innovations & Investing
AI vs. the Silent Killer: How Artificial Intelligence Is Rewriting the Rules of Pancreatic Cancer Diagnosis
It begins, as it so often does, in silence. Pancreatic cancer—one of the most lethal malignancies known to modern medicine—lurks...
Read more
Testing from the Living Room: The FDA’s Approval of Teal Health’s At-Home Cervical Cancer Screen Marks a Watershed in Women’s Health
What if the future of cancer prevention fit inside your mailbox? On May 9, 2025, a quiet yet seismic shift...
Read more
From Data to Diagnosis: How Technology is Rewiring the Practice of Medicine
In a quiet revolution unfolding not in hospital wards but on wrists, in smartphones, and behind cloud-based dashboards, healthcare is...
Read more
Inoculating Against the Incurable: The Promise and Peril of Cancer Vaccines
Few diseases have resisted humanity’s best scientific efforts with the consistency and cruelty of cancer. It mutates, hides, recurs. It...
Read more
Precision at the Molecular Level: How AI is Redefining Prostate Cancer Treatment
In the world of oncology, prostate cancer has long presented a paradox. It is both one of the most common...
Read more
The Brain on Estrogen: Rethinking Appetite Through Neurohormonal Insight
For decades, estrogen has been understood primarily as a reproductive hormone—cyclic, ovarian, and deeply entwined with fertility. But in recent...
Read more
Rethinking the Gut Health Craze: The Science Behind Microbiome Research and Probiotic Skepticism
In recent years, the gut microbiome has emerged as a glamorous frontier in health and wellness, touted as a panacea...
Read more
Donanemab’s FDA Panel Approval: A Breakthrough Moment for Alzheimer’s—and a Cautionary Tale for Biotech
In a highly anticipated decision, an advisory panel to the U.S. Food and Drug Administration (FDA) voted overwhelmingly to support...
Read more
Google’s MedLM and the Future of AI in Healthcare: Promise, Pitfalls, and Polarization
Google's latest foray into healthcare innovation, the announcement of its MedLM artificial intelligence platform, has ignited both excitement and apprehension...
Read more
Private Equity’s Quiet Expansion into Disability Care
There’s a quiet revolution happening in the disability services sector—one that is rarely covered in mainstream media but carries far-reaching...
Read more
How Health Savings Accounts Are Powering the Rise of Direct Pay in Medicine
The American healthcare system is quietly undergoing a financial transformation. As insurance premiums rise and administrative complexity deepens, more patients—and...
Read more
How To Create a Prototype for a Medical Device
Here is a deeper look into the often overlooked yet crucial practices and standards that ensure the highest quality in...
Read more
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more